Acitretin

Nikam, BalkrishnaP; Amladi, Sangeeta; Wadhwa, S. L.

doi:10.4103/0378-6323.25655

Cited by 11 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of occurrence of adverse events in our study was lower than in other reported experiences (23,(25)(26)(27)(28). The very low starting dose and the low mean daily dosage administered in our population may account for this finding, as the incidence of acitretin-associated clinical and laboratory adverse events has been shown to be largely dose dependent (8,9,13).…”

Section: Discussioncontrasting

confidence: 83%

Low-dose Acitretin in Treatment of Plaque-type Psoriasis: Descriptive Study of Efficacy and Safety

Borghi¹,

Corazza²,

Bertoldi³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

The efficacy and safety of acitretin was evaluated retrospectively in a cohort of 46 patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) range 10-42). Patients were treated at an initial dose of 10 mg/day acitretin, which was then gradually increased until the best therapeutic effect with the fewest adverse effects was reached (< 50 mg/day) and later decreased and maintained at the lowest effective dosage. Efficacy measures were: (i) PASI75 (75% improvement) and PASI50 between 10 and 16 weeks; and (ii) PASI75 even after 16 weeks of treatment. At weeks 10-16, PASI75 and PASI50 were achieved by 47.8% and 87% of the patients, respectively. Overall, 67.3% reached PASI75. Adverse events occurred in 18 patients (39.1%); among these, 4 (8.7%) discontinued acitretin. Our findings suggest that acitretin at an initial low, gradually escalating dose, and subsequently maintained at the minimal effective dose, is a suitable treatment option for plaque psoriasis as it provides clear-cut improvement in most treated patients while minimizing the risks of side-effects.

show abstract

Section: Discussioncontrasting

confidence: 83%

Low-dose Acitretin in Treatment of Plaque-type Psoriasis: Descriptive Study of Efficacy and Safety

Borghi¹,

Corazza²,

Bertoldi³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Regarding side effects, 4(12.5%) patients developed alopecia, each of xerophthalmia and cheilitis was seen in 3(9.37%) patients, each of fatigue and pruritus was seen in 2(6.25%) patients and only 1(3.12%) patient developed myalgia. The rate of occurrence of adverse events in our study was lower than in other reported experiences [20][21][22][23] . The low mean daily dosage administered in our population may account for this finding.…”

Section: Methodscontrasting

confidence: 85%

Study of Efficacy and Safety of Acitretin as Monotherapy in the Treatment of Moderate to Severe Plaque Type Psoriasis

Sarkar

Sen²,

Mostofa³

et al. 2020

Faridpur Med Coll J

View full text Add to dashboard Cite

Psoriasis is a chronic papulosquamous disorder with remissions and exacerbations. Varied estimates of the population prevalence of the disease in different parts of the world range from 0.1 - 3%. It is not uncommon in our country. Although there are no treatment options offering a complete cure, a number of options exist for providing symptomatic relief, inducing as well as prolonging remission. Various systemic therapies such as methotrexate, acitretin, cyclosporine, and biologic agents can be used. A review of pharmacokinetics, safety and a discussion of relapse rate establish acitretin, an aromatic retinoid as an efficacious, convenient, oral monotherapy for initial and maintenance of severe psoriasis. A prospective clinical trial was conducted to find out the efficacy and safety of acitretin as monotherapy in the treatment of moderate to severe plaque type psoriasis (PASI range 10-42). Thirty two clinically diagnosed cases of moderate to severe plaque type psoriasis attending the Skin and VD out patient department of Faridpur Medical College Hospital, Faridpur were selected randomly. Majority (46.9%) were between 61 to 80 years of age and only 3.1% patients were in the <20 years age group. The average age was 57.3 years and range was 19-90 years. Majority (68.8%) of the patients were male and 31.2% patients were female. The male female ratio was 2.2:1. After 8 weeks of treatment with acitretin PASI 50 and PASI 75 response rates were 55% and 24% respectively and after 12 weeks of treatment, PASI 50 and PASI 75 response rates were 75% and 50% respectively. As side effects of the treatment, 4(12.5%) patients developed alopecia, each of xerophthalmia and cheilitis was seen in 3(9.37%) patients, each of fatigue and pruritus was seen in 2(6.25%) patients and only 1(3.12%) patient developed myalgia. This study demonstrates that acitretin as monotherapy is effective and safe in the treatment of moderate to severe plaque type psoriasis. Faridpur Med. Coll. J. Jan 2019;14(1): 16-19

show abstract

“…Each capsule contains acitretin, microcrystalline cellulose, sodium ascorbate, gelatin, black monogramming ink and maltodextrin (a mixture of polysaccharides) [2,5,14].…”

Section: Drugmentioning

confidence: 99%

“…Soriatane (Acitretin) is a systemic retinoid and a time-honored treatment for psoriasis and some keratinization disorders [1,2]. It normalizes cellular differentiation and maturation, and it is used also as a chemo-preventive agent against cutaneous malignancies.…”

Section: Introductionmentioning

confidence: 99%

Adverse Effects of Soriatane on Rats Enterocytes: Light Microscopy and Ultrastructural Studies

Hummadi¹

2012

J Cytol Histol

View full text Add to dashboard Cite

Soriatane (Acitretin) drug is a synthetic vitamin A analogue and the main metabolite of etretinate. It is considered to be the latest medicine prescribed to psoriasis patients. However, it is not used frequently because of its side-effect profile. Little is known about the Acitretin intestinal toxicity, so the objective of this study is evaluation of soriatane adverse events in daily practice treatment on the duodenum enterocytes of male rats. Two groups each of 10 Wistar male rats (5-6 weeks old), one of them is the treated group and the other is the control group. The drug was dissolved immediately in distilled water before administration, and given to treated rats by gastric intubation in the morning (0.2 mg/kg/day for 12 months), while the control group received only distilled water. A significant reduction in number and height of villi with increased mucosal thickness. Damage in the duodenum tissues with villi fusion, distortion flattened epithelial cells; intense lamina propria and edema were observed. The ultra-structure alterations were indicated by Golgi apparatus, rough endoplasmic reticulum and mitochondrial atrophy with cristiolysis. Proliferation of smooth endoplasmic reticulum, nuclear deformity and increased number of liposomes were also noted. It may concluded that Soriatane led to irreversible ultra-structural alterations in rat enterocytes after 12 months treatment and precautions should be taken in prescribing acitretin to patients.

show abstract

Acitretin

Cited by 11 publications

References 0 publications

Low-dose Acitretin in Treatment of Plaque-type Psoriasis: Descriptive Study of Efficacy and Safety

Low-dose Acitretin in Treatment of Plaque-type Psoriasis: Descriptive Study of Efficacy and Safety

Study of Efficacy and Safety of Acitretin as Monotherapy in the Treatment of Moderate to Severe Plaque Type Psoriasis

Adverse Effects of Soriatane on Rats Enterocytes: Light Microscopy and Ultrastructural Studies

Contact Info

Product

Resources

About